Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adipose-derived autologous mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
This is an experimental cell therapy being developed by Mayo Clinic for the treatment of moderate to severe medically refractory ulcerative colitis. The therapy consists of adipose-derived autologous mesenchymal stem cells (AD-MSCs) harvested from the patient's own adipose (fat) tissue. The cells are processed and then administered at doses of either 15 million or 30 million cells via intra-arterial delivery using interventional radiology to the inferior mesenteric artery. This innovative delivery method targets the affected area directly, which may enhance effectiveness and reduce side effects compared to standard intravenous administration. The mesenchymal stem cells are believed to work by regenerating damaged tissue and modulating the immune response, potentially addressing the root cause of ulcerative colitis rather than just alleviating symptoms. It is currently being evaluated in a Phase I, open-label clinical trial to assess safety and feasibility.
- Other names
- AD-MSCsAdipose-derived mesenchymal stem cellsAutologous mesenchymal stem cells
Beyond the preview
Go deeper on Adipose-derived autologous mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adipose-derived autologous mesenchymal stem cells.